Talha Badar, specialist in Hematology Oncology based in Mayo Clinic, shared on X:
“First paper from 2025
Role of Allogeneic Hematopoietic Stem Cell Transplantation in Ph+ ALL.
Now we can achieve long-term remission in substantial proportion of patients without transplant: provided they receive potent TKI combination upfront and achieve good molecular response.
Our paper from COMMAND consortium highlighting outcomes in contemporary era AJH 2024.”
Authors: Omer Jamy and Talha Badar
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.